NovaCardia Inc., which has a Phase III product for congestive heart failure, is being acquired by Merck & Co. Inc. for $350 million in stock. (BioWorld Today)

NovaCardia Inc., which has a Phase III product for congestive heart failure, is being acquired by Merck & Co. Inc. for $350 million in stock. (BioWorld Today)